Omega Fund Management, LLC — 13F Holdings & Portfolio
CIK 1637359 · latest 13F-HR filed 2026-08-14
Omega Fund Management, LLC manages $185.7M in 13F-reported U.S. long-equity assets across 10 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are BCAX (29.14%), NUVB (24.72%), KMTS (14.00%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 1, added to 7, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
BOSTON, MA 02199
$185.7M
Long-equity book
10
Distinct positions
2026-06-30
Filed 2026-08-14
+1 / −1 / ↑7 / ↓2
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Nuvation Bio Inc.$11.2M +32.4%
- Beta Bionics Inc.$7.4M +56.4%
- Bicara Therapeutics Inc.$6.5M +13.7%
- Kestra Med Technologies Ltd$5.6M +27.6%
- Alumis Inc.$1.5M +27.7%
Top Trims
- enGene Holdings Inc.-$4.5M -74.6%
- BridgeBio Oncology Therapeutics Inc.-$4.4M -14.9%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. | BCAX | 055477103 | $54.1M | 29.14% | 1,822,150 | SH |
| 2 | Nuvation Bio Inc. | NUVB | 67080N101 | $45.9M | 24.72% | 8,081,089 | SH |
| 3 | Kestra Med Technologies Ltd | KMTS | G52441105 | $26.0M | 14.00% | 1,022,149 | SH |
| 4 | BridgeBio Oncology Therapeutics Inc. | BBOT | 107924102 | $25.1M | 13.50% | 3,289,661 | SH |
| 5 | Beta Bionics Inc. | BBNX | 08659B102 | $20.6M | 11.11% | 1,316,183 | SH |
| 6 | Alumis Inc. | ALMS | 022307102 | $6.8M | 3.66% | 241,255 | SH |
| 7 | Sana Biotechnology, Inc. | SANA | 799566104 | $2.9M | 1.59% | 843,750 | SH |
| 8 | ImageneBio, Inc. | IMA | 45175G207 | $2.7M | 1.45% | 455,361 | SH |
| 9 | enGene Holdings Inc. | ENGNW | 29286M105 | $1.5M | 0.82% | 876,357 | SH |
| 10 | Odyssey Therapeutics Inc. | ODTX | 67613T104 | $54.1K | 0.03% | 2,893 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $185.7M | 10 | 0001193125-26-350681 |
| 2026-03-31 | 2026-05-15 | $163.1M | 10 | 0001193125-26-225480 |
| 2025-12-31 | 2026-02-17 | $286.5M | 11 | 0001193125-26-053268 |
| 2025-09-30 | 2025-11-14 | $222.4M | 12 | 0001193125-25-281790 |